Study participants treated with the monoclonal antibody had a 56% reduction in harmful cholesterol.
Amgen’s PCSK9 inhibitor Repatha (evolocumab) was safe and effective at lowering harmful LDL cholesterol among people with HIV in a recent randomized, double-blind clinical trial, Healio reports.
Findings from the BEIJERINCK trial were presented at the virtual American College of Cardiology Scientific Session and published in the Journal of the American College of Cardiology.
The study randomized 464 people with HIV to receive a placebo or 420 milligrams of Repatha once per month.















